Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 572

NCT07285902

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Treatment group A: HRS9531 injectionn/rn/rn/rn/r
Treatment group B: Semaglutide Injectionn/rn/rn/rn/r

Not shown

  • Treatment group A: HRS9531 injection: endpoint not reported
  • Treatment group B: Semaglutide Injection: endpoint not reported